Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
暂无分享，去创建一个
Hung-Ming Wang | V. Lee | P. Lou | A. Dechaphunkul | C. Yen | J. Mataraza | Shau-Hsuan Li | L. Manenti | B. Ma | A. Spira | Li Zhang | R. Ngan | Zujun Li | D. Lim | A. Sukari | S. Szpakowski | S. McCune | Somvilai Chakrabandhu | J. Guigay | J. Gonzalez-Maffe | P. Chan | C. Even | S. Tanasanvimon | R. Sechaud | Yao Yao | H. Liang